Repository logo
 

Ultra Short Echo Time MRI of Iron-Labelled Mesenchymal Stem Cells in an Ovine Osteochondral Defect Model.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Kaggie, Joshua D 
Markides, Hareklea 
MacKay, James 
Houston, Gavin 

Abstract

Multipotent Mesenchymal Stem/Stromal Cells (MSCs) are widely used in cellular therapy for joint repair. However, the use of MSC therapies is complicated by a lack of understanding of the behaviour of cells and repair within the joint. Current methods of MSC tracking include labelling the cells with Super Paramagnetic Iron Oxide nanoparticles (SPIOs). However, standard acquisition sequences (T2 and T2*) give poor anatomical definition in the presence of SPIOs. To avoid anatomical compromise in the presence of SPIOs, we have investigated the use of Ultra-short Echo Time (UTE) MRI, using a 3D cones acquisition trajectory. This method was used to track SPIO labelled MSC injected into joints containing osteochondral defects in experimental sheep. This study demonstrates that multiple echo times from UTE with 3 T MRI can provide excellent anatomical detail of osteochondral defects and demonstrate similar features to histology. This work also monitors the location of SPIO-labelled cells for regenerative medicine of the knee with MRI, histology, and Prussian blue staining. With these methods, we show that the SPIOs do not hone to the site of defect but instead aggregate in the location of injection, which suggests that any repair mechanism with this disease model must trigger a secondary process.

Description

Keywords

Animals, Disease Models, Animal, Female, Iron, Knee Injuries, Magnetic Resonance Imaging, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Nanoparticles, Sheep, Sheep Diseases

Journal Title

Sci Rep

Conference Name

Journal ISSN

2045-2322
2045-2322

Volume Title

10

Publisher

Springer Science and Business Media LLC

Rights

All rights reserved
Sponsorship
Engineering and Physical Sciences Research Council (EP/K503757/1)
Cancer Research Uk (None)
European Commission Horizon 2020 (H2020) Industrial Leadership (IL) (761214)
This work was supported by GlaxoSmithKline, the Engineering and Physical Sciences Research Council (EPSRC), Arthritis Research UK, European Union's Horizon 2020 research and innovation programme under grant agreement no. 761214, Addenbrooke’s Charitable Trust, and the NIHR Cambridge Biomedical Research Centre.